A Hopeful Leap Forward by Multicentric Cooperation for Precision-Based Therapy for Very Resistant, Relapsed, or Refractory Childhood Leukemia

Pikman and colleagues report the results of a multicentric prospective clinical trial of the leukemia precision-based therapy (LEAP) consortium that combines identification of targetable lesions in drug-resistant childhood leukemia, tiered based on evidence for genomic lesions and drug target, valid...

Full description

Saved in:
Bibliographic Details
Published inCancer discovery Vol. 11; no. 6; pp. 1322 - 1323
Main Authors Bornhauser, Beat C., Bourquin, Jean-Pierre
Format Journal Article
LanguageEnglish
Published United States 01.06.2021
Subjects
Antineoplastic Agents
Child
Genomics
Humans
Leukemia - drug therapy
Leukemia - genetics
Prospective Studies
Translational Research, Biomedical
Online AccessGet full text
ISSN2159-8274
2159-8290
2159-8290
DOI10.1158/2159-8290.CD-21-0258

Cover

More Information
Summary:Pikman and colleagues report the results of a multicentric prospective clinical trial of the leukemia precision-based therapy (LEAP) consortium that combines identification of targetable lesions in drug-resistant childhood leukemia, tiered based on evidence for genomic lesions and drug target, validation of matching small-molecule targeted agents, and treatment of individual patients. The study demonstrates the impact of genomic information on disease classification, treatment guidance, and translational research, but also illustrates the challenges for target prediction and trial design for increasingly heterogeneous and smaller subgroups of patients. .
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
ISSN:2159-8274
2159-8290
2159-8290
DOI:10.1158/2159-8290.CD-21-0258